Systemic administration of AnxA5 or other PS ligands may slow tumor progression by blocking the tumor-supportive properties of apoptotic cells and tumor-derived microvesicles.105 In combination with radio- or chemotherapy, AnxA5 could be used as a natural adjuvant to increase the immunogenicity of dying tumor cells thereby promote an anti-tumor immune response.106 This may be especially helpful in targeting cancer cells that have resisted therapy and are thus prone to recurrence and metastases. The gene discussed is ANXA5; the disease is neoplasm.